MCRB Seres Therapeutics Inc.

2.79
-0.21  -7%
Previous Close 3
Open 2.96
Price To Book -1.64
Market Cap 114,654,581
Shares 41,094,832
Volume 1,028,894
Short Ratio
Av. Daily Volume 430,598

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due early 2020.
SER-109 - ECOSPOR III
Recurrent C. Difficile infection
Phase 2b data due 3Q 2020.
SER-287
Mild-to-Moderate Ulcerative Colitis
Phase 1b data due 2020.
SER-401
Melanoma

Latest News

  1. Do Directors Own Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares?
  2. What Kind Of Shareholders Own Seres Therapeutics, Inc. (NASDAQ:MCRB)?
  3. Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration Safety Alert Related to Use of Fecal Microbiota Transplantation
  4. Microbiome Therapeutics Innovation Group Statement on FDA Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms
  5. Seres Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
  6. The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes
  7. Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
  8. Seres Therapeutics to Present at the Jefferies 2019 Healthcare Conference
  9. Edited Transcript of MCRB earnings conference call or presentation 2-May-19 12:30pm GMT
  10. Seres Therapeutics (MCRB) Reports Q1 Loss, Lags Revenue Estimates
  11. Seres Therapeutics: 1Q Earnings Snapshot
  12. Seres Therapeutics Reports First Quarter Financial Results and Provides Clinical Pipeline Progress Update
  13. Seres Therapeutics, Inc. to Host Earnings Call
  14. Seres Therapeutics to Host First Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on May 2, 2019
  15. Gut Check: The Bacteria In Your Intestines Could Help Cure Cancer
  16. Seres Therapeutics Presents New Preclinical Data Supporting the Development of SER-401 for Immuno-Oncology at the 2019 American Association for Cancer Research Annual Meeting
  17. Edited Transcript of MCRB earnings conference call or presentation 6-Mar-19 1:30pm GMT
  18. Seres Therapeutics (MCRB) in Focus: Stock Moves 6.7% Higher
  19. Seres Therapeutics Options Volume Peaks After AstraZeneca News
  20. Here's Why Seres Therapeutics Stock Soared Today